Clinical Trials on Hemophilia B, Severe

Total 10279 results

Medical University of Vienna

Completed

Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation

Hemophilia A

Austria
University of Aarhus

Completed

Clot Formation and Clot Stability in Patients With Severe Haemophilia A

Hemophilia A

Denmark
JHM BioPharma (Tonghua) Co. , Ltd.

Recruiting

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AbbVie

Completed

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

Japan
Chongqing Claruvis Pharmaceutical Co., Ltd.

Completed

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Croma-Pharma GmbH

Completed

SAVINO (Saypha® Volume LIdocaine in Nasolabial FOlds)

Moderate to Severe Nasolabial Folds

Austria
Allergan

Completed

A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds

Moderate to Severe Nasolabial Folds

United States
Kythera Biopharmaceuticals

Completed

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Patient Experience Study of Deoxycholic Acid Injection

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area (REFINE-1)

Moderate or Severe Submental Fullness

United States, Canada
Cukurova University

Completed

The Effects of Exercises on Gait in Hemophilic Individuals

Hemophilic Arthropathy

Turkey
AMIpharm Co., Ltd.

Completed

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

Moderate or Severe Submental Fullness

Korea, Republic of
Ipsen

Completed

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines (BTX-A-HAC NG)

Moderate to Severe Glabellar Lines

France, Germany
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Germany, France, Belgium, Spain, United Kingdom
Kythera Biopharmaceuticals

Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)

Moderate or Severe Submental Fullness

United Kingdom, Canada, Australia
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States, Canada
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

Moderate to Severe Glabellar Line

Korea, Republic of
Aqpha Medical B.V.

Not yet recruiting

Safety and Performance of PTMC Dermal Filler

Moderate to Severe Nasolabial Fold
Daewoong Pharmaceutical Co. LTD.

Completed

DWP450 for Treating Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Galderma R&D

Completed

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AMIpharm Co., Ltd.

Completed

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat (AYP-101)

Moderate or Severe Submental Fullness

Korea, Republic of
EuBiologics Co.,Ltd

Completed

Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects

Moderate to Severe Glabellar Lines

Korea, Republic of
Allergan

Completed

Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds

Moderate to Severe Nasolabial Folds

Germany, Netherlands
Derming SRL

Completed

Efficacy and Tolerance Evaluation of an Anti-age Food Supplement

Moderate-severe Skin Aging/Photoaging
Kythera Biopharmaceuticals

Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Australia, Canada, United Kingdom
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Belgium, France, Germany, Italy, Spain, United Kingdom
Bernhard Nocht Institute for Tropical Medicine

Not yet recruiting

LAssa Fever Adjunct Treatment With DEXamethasone (LADEX)

Lassa Fever
International AIDS Vaccine Initiative
Coalition for Epidemic Preparedness Innovations

Recruiting

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

Lassa Fever

Ghana, Liberia, Nigeria
University of Oxford
London School of Hygiene and Tropical Medicine; Public Health England; National... and other collaborators

Terminated

Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever

Lassa Fever

Sierra Leone
Beckman Coulter, Inc.

Completed

Evaluation of MDW for Early Detection of Sepsis, Clinical Validity

Sepsis | Severe Sepsis | Severe Infection

France, Spain
The Scientific and Technological Research Council...
MonitorCRO

Completed

Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans

Crimean-Congo Hemorrhagic Fever
Bernhard Nocht Institute for Tropical Medicine
Institut National de la Santé Et de la Recherche Médicale, France; University... and other collaborators

Completed

Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever (SAFARI)

Lassa Fever

Nigeria
Shanghai Belief-Delivery BioMed Co., Ltd
Shanghai MYGT Biopharmaceutical LLC

Recruiting

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

Hemophilia A

China
BioMarin Pharmaceutical

Enrolling by invitation

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401) (GENEr8-LTE)

Hemophilia A

United Kingdom, United States
BioMarin Pharmaceutical

Completed

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg (GENEr8-2)

Hemophilia A

United States
Hospices Civils de Lyon

Completed

Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease (M-HEMORRH'AGE)

Hemophilia

France
Beijing Children's Hospital

Unknown

Pharmacokinetic (PK)Research on Chinese Children of Hemophilia (PK)

Pharmacokinetics

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Epidemiology and Immunology of Hemophilia A Inhibitors

Hemophilia A | Blood Disease
Spark Therapeutics, Inc.

Recruiting

Study of a Gene Therapy Treatment for Hemophilia A (KEYSTONE 1)

Hemophilia A

United States
Radboud University Medical Center
Enzyre B.V.

Not yet recruiting

Version Testing of EnzySystem Version A for Hemophilia A

Hemophilia A

Netherlands
Xue-chun Lu

Recruiting

Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial.

Hemophilia

China
Sanofi

Recruiting

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

Hemophilia A

United States
Montefiore Medical Center
Genentech, Inc.

Not yet recruiting

Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

Hemophilia A

United States
Emory University
Takeda Pharmaceuticals North America, Inc.

Recruiting

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (SAFE)

Hemophilia A

United States
Washington Institute for Coagulation
Genentech, Inc.

Recruiting

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A (EmiMSK)

Hemophilia A

United States
Emory University
Octapharma

Recruiting

Treatment of Hemophilia A Patients With FVIII Inhibitors (MOTIVATE)

Hemophilia A

United States, Germany
Sinocelltech Ltd.

Recruiting

Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

Hemophilia A

China
Medical College of Wisconsin

Recruiting

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

Hemophilia A

United States
Takeda

Completed

A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions

Hemophilia

France

3

Subscribe